Waldenstrom Macroglobulinemia clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 18 years and up
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
San Francisco, California and other locations